Elastin-like polypeptides (ELP) aggregate in response to mild hyperthermia, but remain soluble under normal physiological conditions. ELP macromolecules can accumulate in solid tumors because of the enhanced permeability and retention effect.
Abstract
Elastin-like polypeptides (ELP) aggregate in response to mild hyperthermia, but remain soluble under normal physiological conditions. ELP macromolecules can accumulate in solid tumors because of the enhanced permeability and retention effect.
Tumor retention of ELPs can be further enhanced through hyperthermia-induced aggregation of ELPs by local heating of the tumor. We evaluated the therapeutic potential of ELPs in delivering doxorubicin (Dox) in the E0771 syngeneic mouse breast cancer model. The ELP-Dox conjugate consisted of a cell penetrating peptide at the Nterminus and the 6-maleimidocaproyl hydrazone derivative of doxorubicin at the Cterminus of ELP. The acid-sensitive hydrazone linker ensured release of Dox in the lysosomes/endosomes after cellular uptake of the drug conjugate. ELP-Doxo dosed at 5 mg Dox equivalent/kg, extended the plasma half-life of Dox to 5.5 hours. Additionally, tumor uptake of ELP-Dox increased 2-fold when hyperthermia was applied, and was also enhanced compared to free Dox. Although high levels of Dox were found in the heart of animals treated with free Dox, no detectable levels of Dox were found in ELPDox treated animals indicating a correlation between tumor targeting and reduction of potential cardiac toxicity of ELP-Dox. At an optimal dose of 12 mg Dox equivalent/kg, ELP-Dox in combination with hyperthermia induced a complete tumor growth inhibition, which was distinctly superior to free drug which only moderately inhibited tumor growth.
In summary, our findings demonstrate that thermal targeting of ELP increases the potency of doxorubicin underlying the potential of exploiting ELPs to enhance the therapeutic efficacy of conventional anticancer drugs.
Introduction
Chemotherapy is the mainstay for treating different types of breast cancer, especially in the neoadjuvant and palliative setting. The effective use of the most common chemotherapeutics including doxorubicin, epirubicin, paclitaxel is however, often limited by their narrow therapeutic window resulting in unacceptable toxicity, lack of tumor selectivity, and/or multidrug resistance. Targeting strategies that can deliver these drugs specifically to the tumor site is thus highly desirable and could result in an improved therapeutic index and concomitant benefit for the patient.
In this study, we describe a thermally responsive drug delivery platform technology based on the genetically engineered biopolymer elastin-like polypeptide (ELP) that targets solid tumors by combining passive tumor targeting strategy with the application of mild hyperthermia (1) (2) (3) (4) (5) (6) . ELPs undergo inverse phase transition at a specific temperature known as inverse transition temperature (T t ), below which they stay in solution and above which, due to collapse of the hydrophobic structure form aggregates (7) . This process is completely reversible. ELP is composed of repetitive units of Val-Prol-Gly-Xaa-Gly, where Xaa is a guest residue that can be any amino acid except proline. The number of repeats as well as the molecular composition of Xaa directly influence the T t of ELP (8) . Compared to low-molecular weight drugs ELPs remain in blood circulation with a half-life of ~8.7 h (9) sufficient for passive tumor targeting through the enhanced permeability and retention (EPR) effect characterized by hypervasculature and an impaired lymphatic drainage system of the tumor tissue (10) , and thermally responsive ELPs can be actively targeted to the tumor tissue by application of local hyperthermia on the tumor (6) . ELPs are conveniently expressed in E. coli and purified in high yields using inverse thermal cycling (11) , and they have a defined molecular weight, advantages that set ELPs apart from synthetic polymers with similar properties.
Recently, Mackay et al. reported that conjugates of hydrophilic ELP (T t >>
42 °C) and doxorubicin have enhanced anti-tumor activity over doxorubicin against C26 murine colon carcinoma tumors in BALB/c mice (12). However, since the ELP variant used in this study was not responsive to mild hyperthermia, the thermal targeting properties of ELP could not be exploited. Because ELP is a thermally responsive molecule, drug delivery by ELP should be enhanced in response to the temperature difference between the systemic environment and the tumor region which is exposed to hyperthermia. Therefore, we used a thermally responsive ELP1 variant (59 kDa) that has T t close to 40 °C to evaluate the enhancement of doxorubicin delivery by the application of focused mild hyperthermia on the tumor. Additionally, we modified the N-terminus of ELP1 with the cell penetrating peptide, SynB1 for enhanced intratumoral and intracellular uptake (13-15). The cell penetrating thermally responsive SynB1-ELP1 polypeptide was conjugated to a thiol-reactive doxorubicin prodrug. This prodrug of doxorubicin, (6-maleimidocaproyl) hydrazone of doxorubicin (DOXO-EMCH, 1) binds rapidly and selectively to cysteine-34 of circulating albumin in situ and has marked anti-tumor activity in pre-clinical studies (16) (17) (18) (19) and in a phase I clinical trial (20) . DOXO-EMCH, meanwhile renamed is scheduled to enter a sarcoma phase 2 study (see www.cytrx.com).
DOXO-EMCH is a valid candidate to evaluate thermal targeting by ELP because the maleimide moiety on DOXO-EMCH allows for selective conjugation to cysteine residues at the C-terminus of ELP. Additionally, the acid-sensitive hydrazone linker acts as a predetermined breaking point for ensuring effective cleavage of the drug either in the slightly acidic tumor microenvironment or after intracellular uptake in the acidic compartments of the endosomes and/or lysosomes (20) . Since Doxo-EMCH delivered by SynB1-ELP ultimately results in the delivery of doxorubicin (Dox), the ELPdoxorubicin delivery system is simply referred to as SynB1-ELP-Dox. In this report, we show that thermal targeting of Dox delivered by SynB1-ELP enhances its tumor uptake, plasma kinetics, and maximum tolerated dose compared to free Dox, resulting in a potent anti-cancer agent capable of stabilizing disease progression.
Materials and Methods

Synthesis and conjugation of DOXO-EMCH to SynB1-ELP
The thermally responsive SynB1-ELP1 and the thermally insensitive SynB1-ELP2 constructs were cloned as described (21) with three Gly-Gly-Cys repeats at the Cterminus for conjugation with DOXO-EMCH ( Figure 1A ). ELP2 (61 kDa, T t ~ 70 °C) is a size-matched control for ELP1 and is used to parse the non-specific effects of hyperthermia (21) . The polypeptides were expressed in E. coli using the hyperexpression protocol and purified by inverse thermal cycling (11).
Doxorubicin was derivatized at its C-13 keto position with a maleimidocaproyl hydrazide linker yielding (6-maleimidocaproyl)hydrazone derivative of Dox (DOXO-EMCH, 1, Figure 1B ) which was covalently linked to the three cysteine residues on ELP as described (17, 22) . Briefly, the SynB1-ELP1 or SynB1-ELP2 polypeptide was conjugated to DOXO-EMCH in a Michael addition by incubating 125 μM protein with 10- 
Thermal Characterization of ELP-Dox
SynB1-ELP1 labeled with DOXO-EMCH was diluted to various concentrations of ELP in 100% serum. The solution was heated at a rate of 1 °C/min from 20 to 80 °C, and the resulting turbidity was measured as a function of temperature (Cary, Varian Instruments). The percentage of maximum absorbance at 600nm was calculated for each dataset, and T t was defined as the temperature at which 50% of the maximum was observed. T t versus concentration curves were fitted to a logarithmic fit to estimate the thermal targeting range of the SynB1-ELP-Dox conjugates. 
Intracellular distribution
E0771 cells at ~50% confluency were exposed to 40 µM free Dox or SynB1-ELP1-Dox for 1 min or 20 µM free Dox or SynB1-ELP1-Dox for 30 or 240 min at 37 °C.
To determine the effect of temperature on Dox distribution, cells were exposed to 20 µM SynB1-ELP1-Dox or free Dox for 1 h at 37 or 42 °C, after which the drugs were replaced with fresh medium and cells were incubated at 37 °C for 24 h. All treated cells were rinsed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. After rinsing with PBS for three times, cells were visualized for Dox fluorescence using a laser scanning confocal microscope (TS2 Leica). All treatment concentrations were based on Dox equivalent. 
Pharmacokinetics study
Mice bearing ~250 mm μL/well. Dox fluorescence was measured at 485 nm excitation and 590 nm emission in a plate reader (BioTek). The raw data was fitted to a free Dox standard curve to estimate Dox plasma concentration with respect to time. Plasma clearance data were fitted to a two-compartmental model using Microcal Origin as described (6) .
Biodistribution study
Dox distribution was measured using tumors and hearts harvested 6 h after drug administration described above. Tumors and hearts were excised, snap-frozen in liquid nitrogen and stored at -80 °C. Dox concentration was determined as described (12): briefly, tissues were weighed, suspended in 1.5 mL of acidified isopropanol, Mice bearing ~150 mm 3 tumor were injected with 5 mg/kg Dox equivalent of free Dox, thermally responsive SynB1-ELP1-Dox, or thermally insensitive SynB1-ELP2-Dox on d0, d2, and d4 intravenously via the femoral vein. Additionally, 280 mg/kg of SynB1-ELP1, the equivalent dose of protein present in the SynB1-ELP1-Dox treatment, was administered to the animals to rule out the toxicity of the unlabeled carrier. Animals in the hyperthermia group were heated using the heating protocol as described above.
Tumor measurement (width 2 x length/2) and body weight were recorded every day after treatment. Animals were sacrificed on d14, when the control tumor size reached 2000 mm 3 . Tumors were harvested and weighed after euthanasia.
Maximum tolerated dose study
In a dose finding study, non-tumor bearing mice were injected with free drug at 8, Mice bearing tumors at ~150 mm 3 were injected with the MTD of free drug (8 mg/kg), or the MTD of SynB1-ELP1-Dox (12 mg/kg) on d0, d2, and d4 intravenously via the femoral vein. Additionally, 650 mg/kg of SynB1-ELP1, the equivalent dose of protein present in the SynB1-ELP1-Dox treatment, was administered to the animals. Animals in the hyperthermia group were heated using the heating protocol described above. Tumor volume and body weight were measured daily up to day 14 at which point animals were sacrificed, and tumors were harvested and weighed.
Statistical Analysis
A one-way ANOVA with Bonferroni tests for pair-wise comparison of treatment groups was performed to analyze the statistical differences between the treatment groups and the untreated control.
Results and Discussion
Thermal characterization of SynB1-ELP-Dox
To attach the cargo drug DOXO-EMCH to ELP, we designed three cysteine residues at the carboxy terminus of ELP that were separated by diglycine spacers 
lower micromolar range suitable for thermal targeting in animals ( Figure 1C ). At the same time, the T t of SynB1-ELP2-Dox was detected at T>>37 °C, confirming that it is a suitable control to assess the nonspecific effect of hyperthermia.
SynB1-ELP1-Dox intracellular distribution
Previous studies with conjugates of DOXO-EMCH and albumin have shown that Dox does not enter the nucleus but localizes in the cytoplasm, primarily in mitochondria and golgi apparatus (26). Therefore, we evaluated the subcellular distribution of Doxo-EMCH delivered by SynB1-ELP1 by confocal microscopy. Dox delivered by SynB1-ELP1 exhibited a time-dependent nuclear distribution compared to free Dox that displayed nuclear localization immediately after treatment (Figures 2A-B 
hydrazone linker releases Dox inside the cell. The cytoplasmic distribution of SynB1-ELP1 observed in a previous study (15) and the results of this data indicate that Dox is being cleaved from the ELP carrier intracellularly and being diffused to the nucleus where it acts in analogy to free Dox.
SynB1-ELP1-Dox pharmacokinetics and tumor distribution
Since unmodified ELP1 has a terminal plasma half-life of nearly 8 h (9) Table S1 ). The reported terminal half-life of Dox in C57BL/6 mice is 31.8 min (28), nearly 10-fold faster than ELPconjugated Dox suggesting that ELP conjugation with Dox extends its systemic circulation time compared to free Dox.
To evaluate whether Dox tumor levels were enhanced by thermal targeting of ELP over free Dox, tumor samples were analyzed for Dox fluorescence. Additionally, since Dox accumulation in the heart is a major concern, we also assayed heart samples from the treated animals. With respect to Dox levels in the tumor, more than 2-fold With respect to Dox levels in the heart, the fluorescence intensity of Dox from animals treated with SynB1-ELP1-Dox could not be detected over the control background signal. However, at the same dose of free Dox, we detected high levels of Dox in the heart ( Figure 3D ). Given that Dox related cardiotoxcitiy is a dose-limiting side-effect, this observation can have meaningful implications in the therapeutic use of ELP-Dox. We expect that through the means of thermal targeting, ELP-Dox can potentially reduce cardiotoxicity of Dox by steering it away from the heart and targeting it to the tumor. This is further supported by the findings that chronic treatment with DOXO-EMCH resulted in reduced cardiomyopathy compared to free Dox in rats (19) . 
Hyperthermia enhances tumor inhibition by SynB1-ELP1-Dox
The antitumor potential of SynB1-ELP1-Dox in combination with hyperthermia was evaluated and compared with that of standard doxorubicin at an equimolar dose of 5 mg/kg given on day 0, 2 and 4. Fourteen days after treatment, mice treated with SynB1-ELP1-Dox in conjunction with hyperthermia had a mean tumor volume that was nearly 4-fold smaller than the saline treated control tumors and nearly 2.5-fold smaller than the SynB1-ELP1-Dox without hyperthermia treated group ( Figure 4A ). In the presence of hyperthermia both SyB1-ELP1-Dox and free Dox exerted similar anti-tumor effect. A 2-fold enhancement of anti-tumor activity of free Dox was seen in the presence of hyperthermia compared to when no hyperthermia was used. This could be explained by the synergistic effect of hyperthermia on doxorubicin toxicity through increased perfusion and vascular fenestration (29-31). However, at the same dose, the thermally insensitive variant SynB1-ELP2-Dox had no effect on tumor inhibition either in the presence or absence of hyperthermia ( Figure 4C) indicating that hyperthermia-mediated aggregation of ELP1 is necessary for the enhanced anti-tumor activity of SynB1-ELP1-Dox. This also underlies possibly difference in response of free Dox versus Dox-conjugated to SynB1-ELP to hyperthermia. Furthermore, the protein carrier, SynB1-ELP1 had no effect on tumor inhibition compared to the untreated control ( Figure 4C ) indicating that the carrier is non-toxic. Most importantly, under our heating protocol, hyperthermia alone had no effect on tumor growth. Tumor weights from these animals correlated with the tumor growth curve data (Supplementary Figure 1S) . treatment was observed well above the 80% pre-treatment weight limit indicating that the animals are able to tolerate the therapy (Figures 4B and 4D) .
Maximum tolerated dose of SynB1-ELP1-Dox
Even though SynB1-ELP1-delivered Dox and free Dox had similar potencies for tumor reduction in equimolar comparison (Figure 4) , we expected that the ELP-fused form of the drug would have higher a maximum tolerated dose (MTD). Based on our definition of MTD, both free Dox and SynB1-ELP1-Dox were found to be highly toxic at a dose higher than 20 mg/kg Dox equivalent ( Table 1) . Treatment with 10 mg/kg free Dox did not result in complete survival. However, at 8 mg/kg all the free Dox treated animals survived with weight loss < 20%. Thus, the MTD of free Dox was set at 8 mg/kg. Animals were able to tolerate both 10 mg/kg and 15 mg/kg of SynB1-ELP1-Dox treatments ( Table 1) . To evaluate the effect of hyperthermia on the MTD of SynB1-ELP1-Dox, tumor bearing animals were used so that focused heat could be applied to the tumor. In conjunction with hyperthermia, a dose of 15 mg/kg of SynB1-ELP1-Dox was poorly tolerated by the animals. At a slightly lower dose of 12 mg/kg however, animal tolerance of the treatment was acceptable resulting in a complete survival ( Table   1) . Therefore, the MTD of SynB1-ELP1-Dox was set at 12 mg/kg. However, this dose was given three times so that the cumulative dose of SynB1-ELP1-Dox was 36 mg/kg (Table 1) 
Complete tumor inhibition by SynB1-ELP1-Dox
The therapeutic efficacy of SynB1-ELP1-Dox against the E0771 murine breast tumors was evaluated and compared to free doxorubicin at the respective MTD. 
